Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter

Cellular Physiology and Biochemistry

Volumn 22, Issue 1-4, 2008, Pages 1-14

  Shen, Hong ^a   Zhang, Yu ^a   Ding, Hong ^a   Wang, Xu ^a   Chen, Lili ^a   Jiang, Hualiang ^a   Shen, Xu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Farnesoid X receptor; Glucose metabolism; Glucose transporter 4; Type 2 diabetes

Indexed keywords

CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; GLUCOSE TRANSPORTER 4; RETINOID X RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS;

EID: 51149116345     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000149779     Document Type: Article

References (56)

1. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-486.
2. Kahn BB: Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes 1996;45:1644-1654.
3. Stephens JM, Pilch PF: The metabolic regulation and vesicular transport of GLUT4, the major insulin-responsive glucose transporter. Endocr Rev 1995;16:529-546.
4. Berger J, Biswas C, Vicario PP, Strout HV, Saperstein R, Pilch PF: Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting. Nature 1989;340:70-72.
5. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP: Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 1991;87:1072-1081.
6. Garvey WT, Maianu L, Hancock JA, Golichowski AM, Baron A: Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 1992;41:465-475.
7. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001;409:729-733.
8. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB: Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 1993;268:22243-22246.
9. Tsao TS, Stenbit AE, Factor SM, Chen W, Rossetti L, Charron MJ: Prevention of insulin resistance and diabetes in mice heterozygous for GLUT4 ablation by transgenic complementation of GLUT4 in skeletal muscle. Diabetes 1999;48:775-782.
10. Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, Zong H, Dong J, Kahn CR, Kahn BB, Shulman GI: Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 2001;108:153-160.
11. Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI: Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha. J Biol Chem 2003;278:48283-48291.
12. Cooke DW, Lane MD: The transcription factor nuclear factor I mediates repression of the GLUT4 promoter by insulin. J Biol Chem 1999;274:12917-12924.
13. Dowell P, Cooke DW: Olf-1/early B cell factor is a regulator of glut4 gene expression in 3T3-L1 adipocytes. J Biol Chem 2002;277:1712-1718.
14. Thomson MJ, Williams MG, Frost SC: Development of insulin resistance in 3T3-L1 adipocytes. J Biol Chem 1997;272:7759-7764.
15. Chiang JY: Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002;23:443-463.
16. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B: The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281:11039-11049.
17. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA: Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000;275:10638-10647.
18. Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC, Staels B: FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003;124:1926-1940.
19. Wang H, Chen J, Hollister K, Sowers LC, Forman BM: Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-553.
20. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ: Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000;6:507-515.
21. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart JC, Dallongeville J, Hum DW, Kuipers F, Staels B: Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002;109:961-971.
22. Urizar NL, Dowhan DH, Moore DD: The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 2000;275:39313-39317.
23. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA: Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001;15:1720-1728.
24. Ruhl CE, Everhart JE: Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000;31:299-303.
25. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, Kuipers F, Staels B: Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004;53:890-898.
26. Rizzo G, Disante M, Mencarelli A, Renga B, Gioiello A, Pellicciari R, Fiorucci S: The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 2006;70:1164-1173.
27. Ma K, Saha PK, Chan L, Moore DD: Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109.
28. Frost SC, Lane MD: Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J Biol Chem 1985;260:2646-2652.
29. Cao X, Liu W, Lin F, Li H, Kolluri SK, Lin B, Han YH, Dawson MI, Zhang XK: Retinoid X receptor regulates Nur77/TR3-dependent apoptosis [corrected] by modulating its nuclear export and mitochondrial targeting. Mol Cell Biol 2004;24:9705-9725.
30. Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL, Muller M: Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 2002;35:589-596.
31. Gray S, Feinberg MW, Hull S, Kuo CT, Watanabe M, Sen-Banerjee S, DePina A, Haspel R, Jain MK: The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J Biol Chem 2002;277:34322-34328.
32. Sun T, Wang Q, Yu Z, Zhang Y, Guo Y, Chen K, Shen X, Jiang H: Hyrtiosal, a PTP1B Inhibitor from the Marine Sponge Hyrtios erectus, Shows Extensive Cellular Effects on PI3K/AKT Activation, Glucose Transport, and TGFbeta/Smad2 Signaling. Chembiochem 2007;8:187-193.
33. Im SS, Kwon SK, Kang SY, Kim TH, Kim HI, Hur MW, Kim KS, Ahn YH: Regulation of GLUT4 gene expression by SREBP-1c in adipocytes. Biochem J 2006;399:131-139.
34. Brazil DP, Hemmings BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-664.
35. Du K, Herzig S, Kulkarni RN, Montminy M: TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 2003;300:1574-1577.
36. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP: Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005;146:984-991.
37. Armoni M, Kritz N, Harel C, Bar-Yoseph F, Chen H, Quon MJ, Karnieli E: Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 2003;278:30614-30623.
38. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, Saez E, Tontonoz P: Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 2003;100:5419-5424.
39. Mak PA, Kast-Woelbern HR, Anisfeld AM, Edwards PA: Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 2002;43:2037-2041.
40. Kurtz W, Leuschner U, Hellstern A, Janka P: Sex differences in rat liver bile acids. Hepatogastroenterology 1982;29:227-231.
41. Kuroki S, Muramoto S, Kuramoto T, Hoshita T: Sex differences in gallbladder bile acid composition and hepatic steroid 12 alpha-hydroxylase activity in hamsters. J Lipid Res 1983;24:1543-1549.
42. Bossard R, Stieger B, O'Neill B, Fricker G, Meier PJ: Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest 1993;91:2714-2720.
43. Barros RP, Machado UF, Warner M, Gustafsson JA: Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci U S A 2006;103:1605-1608.
44. Olson AL, Pessin JE: Transcriptional regulation of the human GLUT4 gene promoter in diabetic transgenic mice. J Biol Chem 1995;270:23491-23495.
45. Tsunoda N, Cooke DW, Ikemoto S, Maruyama K, Takahashi M, Lane MD, Ezaki O: Regulated expression of 5′-deleted mouse GLUT4 minigenes in transgenic mice: effects of exercise training and high-fat diet. Biochem Biophys Res Commun 1997;239:503-509.
46. Kaestner KH, Christy RJ, Lane MD: Mouse insulin-responsive glucose transporter gene: characterization of the gene and trans-activation by the CCAAT/enhancer binding protein. Proc Natl Acad Sci U S A 1990;87:251-255.
47. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B: Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259-272.
48. Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B: Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003;125:544-555.
49. Dubois MJ, Bergeron S, Kim HJ, Dombrowski L, Perreault M, Fournes B, Faure R, Olivier M, Beauchemin N, Shulman GI, Siminovitch KA, Kim JK, Marette A: The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med 2006;12:549-556.
50. Zhao A, Lew JL, Huang L, Yu J, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Blevins RA, Pelaez F, Wright SD, Cui J: Human kininogen gene is transactivated by the farnesoid X receptor. J Biol Chem 2003;278:28765-28770.
51. Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R, Fiorucci S: The methyl transferase PRMT1 functions as coactivator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol 2005;68:551-558.
52. Kassam A, Miao B, Young PR, Mukherjee R: Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J Biol Chem 2003;278:10028-10032.
53. Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
54. Katome T, Obata T, Matsushima R, Masuyama N, Cantley LC, Gotoh Y, Kishi K, Shiota H, Ebina Y: Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol Chem 2003;278:28312-28323.
55. Shepherd PR, Kahn BB: Glucose transporters and insulin actioni-mplications for insulin resistance and diabetes mellitus. N Engl J Med 1999;341:248-257.
56. Claudel T, Sturm E, Kuipers F, Staels B: The farnesoid X receptor: a novel drug target? Expert Opin Investig Drugs 2004;13:1135-1148.